γ-gt

γ-GT (H-GLA(PNA)-OH) is used as a synthetic substrate for gamma-glutamyltransferase (GGT) to determine GGT activity.

GT-1 (LCB10-0200) is a siderophore-linked cephalosporin compound that effectively combats clinical isolates of various bacterial species, including P. aeruginosa, Klebsiella oxytoca, Proteus spp., Serratia marcescens, and Enterobacter aerogenes.

GT-2394 is a histamine H3 receptor agonist.

GT-2227 is a histamine H3 receptor antagonist.

GT-0198 is a novel glycine transporter 2 inhibitor showed activity in a mouse model of neuropathic pain. GT-0198 inhibited the function of glycine transporter 2 (GlyT2) in human GlyT2-expressing HEK293 cells and did not bind various major transporters or receptors of neurotransmitters in a competitive manner. GT-0198 is considered to be a comparatively selective GlyT2 inhibitor. GT-0198 is a structurally novel GlyT2 inhibitor bearing a phenoxymethylbenzamide moiety with in vivo efficacy in behavioral models of neuropathic pain.

GT-055 (LCB18-055) is a novel inhibitor of broad-spectrum β-lactamase.

GT 949 is a selective excitatory positive allosteric modulator of amino acid transporter-2 (EAAT2) (EC50: 0.26 nM).

GT-2331 is a histamine H3 receptor antagonist.

Ganglioside GT1b is a trisialoganglioside that is characterized by having two sialic residues linked to the inner galactose unit. It binds to the neurotoxins botulinum toxin serotype A (BTxA), BTxA heavy chain, and tetanus toxin with IC50 values of 11, 0.74, and 7.2 μM, respectively.[1] Ganglioside GT1b-containing liposomes bind to the major coat protein VP1 from Merkel cell polyomavirus (MCPyV), which has been identified in Merkel cell carcinomas, identifying ganglioside GT1b as a putative MCPyV receptor. [2] Ganglioside GT1b decreases production of IL-6, IL-10, IgG, IgM, and IgA in human peripheral blood mononuclear cells (PBMCs) by 31.4, 30.5, 60, 59.5, and 58%, respectively, when used at a concentration of 10 μM [3] . Ganglioside GT1b mixture contains ganglioside GT1b molecular species with C18:1 and C20:1 sphingoid backbones.

GT 2016 is a H3 receptor antagonist.

GT951 is a EAAT2 activator.

GT-11 is an inhibitor of dihydroceramides (DHCer) desaturase activity.